NO20006482L - 4-benzyl piperidinalkylsulfoksy-heterocykler og deres anvendelse som subtype-selektive NMDA reseptorantagonister - Google Patents

4-benzyl piperidinalkylsulfoksy-heterocykler og deres anvendelse som subtype-selektive NMDA reseptorantagonister

Info

Publication number: NO20006482L
Authority: NO; Norway
Prior art keywords: heterocycles; receptor antagonists; nmda receptor; alkylsulfoxy; selective nmda
Prior art date: 1998-06-26

Application number

NO20006482A

Other languages

English (en)

Norwegian (no)

Other versions

NO20006482D0 (no

Inventor

Jonathan L Wright

Suzanne Ross Kesten

Ravindra B Upsani

Nancy C Lan

Original Assignee

Warner Lambert Co

Cocensys Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-06-26

Filing date

2000-12-19

Publication date

2000-12-19

2000-12-19 Application filed by Warner Lambert Co, Cocensys Inc filed Critical Warner Lambert Co

2000-12-19 Publication of NO20006482D0 publication Critical patent/NO20006482D0/no

2000-12-19 Publication of NO20006482L publication Critical patent/NO20006482L/no

Links

229940127523 NMDA Receptor Antagonists Drugs 0.000 title abstract 2
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 abstract 1
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 abstract 1
208000018737 Parkinson disease Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Cardiology (AREA)
Ophthalmology & Optometry (AREA)
Heart & Thoracic Surgery (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Pulmonology (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

NO20006482A 1998-06-26 2000-12-19 4-benzyl piperidinalkylsulfoksy-heterocykler og deres anvendelse som subtype-selektive NMDA reseptorantagonister NO20006482L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US9091498P	1998-06-26	1998-06-26
PCT/US1999/014291 WO2000000197A1 (en)	1998-06-26	1999-06-25	4-benzyl piperidine alkylsulfoxide heterocycles and their use as subtype-selective nmda receptor antagonists

Publications (2)

Publication Number	Publication Date
NO20006482D0 NO20006482D0 (no)	2000-12-19
NO20006482L true NO20006482L (no)	2000-12-19

Family

ID=22224939

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20006482A NO20006482L (no)	1998-06-26	2000-12-19	4-benzyl piperidinalkylsulfoksy-heterocykler og deres anvendelse som subtype-selektive NMDA reseptorantagonister

Country Status (28)

Country	Link
US (1)	US6284774B1 (is)
EP (1)	EP1089735B1 (is)
JP (1)	JP2002519322A (is)
KR (1)	KR20010053170A (is)
CN (1)	CN1304307A (is)
AP (1)	AP2000001949A0 (is)
AT (1)	ATE297207T1 (is)
AU (1)	AU769650B2 (is)
BG (1)	BG105082A (is)
BR (1)	BR9911575A (is)
CA (1)	CA2327888A1 (is)
DE (1)	DE69925730T2 (is)
EA (1)	EA200100058A1 (is)
EE (1)	EE200000778A (is)
ES (1)	ES2244201T3 (is)
HU (1)	HUP0102471A2 (is)
ID (1)	ID28005A (is)
IL (1)	IL138949A0 (is)
IS (1)	IS5667A (is)
NO (1)	NO20006482L (is)
NZ (1)	NZ508808A (is)
OA (1)	OA11570A (is)
PE (1)	PE20000728A1 (is)
PL (1)	PL345024A1 (is)
SK (1)	SK19512000A3 (is)
TR (1)	TR200003888T2 (is)
WO (1)	WO2000000197A1 (is)
ZA (1)	ZA200005848B (is)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6476041B1 (en) *	1999-10-29	2002-11-05	Merck & Co., Inc.	1,4 substituted piperidinyl NMDA/NR2B antagonists
UA73749C2 (en) *	1999-11-01	2005-09-15		Diarylenines
OA12253A (en) *	2000-04-26	2006-05-11	Warner Lambert Co	Cyclohexylamine derivative as subtype selective NMDA receptor antagonists.
CA2410660A1 (en) *	2000-06-01	2001-12-06	Warner-Lambert Company	Cyclohexylamine derivatives as subtype selective nmda receptor antagonists
AU2001269540A1 (en)	2000-07-18	2002-01-30	Sumitomo Pharmaceuticals Co. Ltd.	Serotonin reuptake inhibitors
IL145584A0 (en)	2000-10-02	2002-06-30	Pfizer Prod Inc	Nmda nr2b antagonists for treatment
HU227197B1 (en)	2000-10-24	2010-10-28	Richter Gedeon Nyrt	Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them
EA005974B1 (ru)	2001-02-23	2005-08-25	Мерк Энд Ко., Инк.	N-замещенные неарильные гетероциклические антагонисты nmda/nr2b
JP2005506292A (ja) *	2001-03-08	2005-03-03	エモリー　ユニバーシティ	ｐＨに依存するＮＭＤＡレセプターアンタゴニスト
CA2443108A1 (en)	2001-04-03	2002-10-17	Merck & Co. Inc.	N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists
CA2381630A1 (en) *	2001-04-23	2002-10-23	Leonard Theodore Meltzer	Method for preventing dyskinesias
DE60228969D1 (is)	2001-07-24	2008-10-30	Richter Gedeon Nyrt
US20030211040A1 (en)	2001-08-31	2003-11-13	Paul Greengard	Phosphodiesterase activity and regulation of phosphodiesterase 1B-mediated signaling in brain
ES2351303T3 (es) *	2001-12-11	2011-02-02	University Of Virginia Patent Foundation	Utilización de pramipexol para el tratamiento de la esclerosis lateral amiotrófica.
US20060281797A1 (en) *	2001-12-11	2006-12-14	University Of Virginia Patent Foundation	Neurorestoration with R(+) Pramipexole
US20040082543A1 (en) *	2002-10-29	2004-04-29	Pharmacia Corporation	Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain
US7732162B2 (en)	2003-05-05	2010-06-08	Probiodrug Ag	Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
WO2006058236A2 (en)	2004-11-24	2006-06-01	Neuromolecular Pharmaceuticals, Inc.	Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease
EP2425845A1 (en) *	2004-12-23	2012-03-07	Voyager Pharmaceutical Corporation	Acetylcholinesterase Inhibitors and leuprolide acetate for the treatment of Alzheimer's disease
ES2334061T3 (es) *	2005-08-15	2010-03-04	University Of Virginia Patent Foundation	Neurorrestauracion con pramipexol r(+).
US8518926B2 (en)	2006-04-10	2013-08-27	Knopp Neurosciences, Inc.	Compositions and methods of using (R)-pramipexole
PL2026803T3 (pl)	2006-05-16	2012-05-31	Knopp Neurosciences Inc	Kompozycje R(+) i S(-) pramipeksolu i sposoby ich zastosowania
JP5379692B2 (ja)	2006-11-09	2013-12-25	プロビオドルグエージー	潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体
EP2091948B1 (en)	2006-11-30	2012-04-18	Probiodrug AG	Novel inhibitors of glutaminyl cyclase
US8524695B2 (en)	2006-12-14	2013-09-03	Knopp Neurosciences, Inc.	Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
CA2679446C (en)	2007-03-01	2016-05-17	Probiodrug Ag	New use of glutaminyl cyclase inhibitors
EP2137171A4 (en)	2007-03-14	2010-05-19	Knopp Neurosciences Inc	SYNTHESIS OF BENZOTHIAZOLE DIAMINES SUBSTITUTED AND PURIFIED FROM THE CHIRAL PERSPECTIVE
US9656991B2 (en)	2007-04-18	2017-05-23	Probiodrug Ag	Inhibitors of glutaminyl cyclase
CN103497114A (zh)	2007-06-29	2014-01-08	埃莫里大学	用于神经保护的nmda受体拮抗剂
DE102007047737A1 (de)	2007-10-05	2009-04-30	Merck Patent Gmbh	Piperidin- und Piperazinderivate
TWI410420B (zh)	2008-02-05	2013-10-01	Dainippon Sumitomo Pharma Co	苄基哌啶化合物
BRPI0910575A2 (pt) *	2008-04-18	2017-06-06	Arizona Board Of Regents A Body Corp Of The State Of Arizona Acting For And Behalf Of The Univ Of Ar	métodos para tratar degeneração macular relacionada com a idade, para limitar desenvolvimento de degeneração macular relacionada com a idade, e para identificar compostos para tratar degeneração macular relacionada com a idade, e, composição
US20110190356A1 (en)	2008-08-19	2011-08-04	Knopp Neurosciences Inc.	Compositions and Methods of Using (R)- Pramipexole
HUP0900130A3 (en)	2009-03-03	2012-02-28	Richter Gedeon Nyrt	Novel crystalline hydrate, amorphous and polymorphic forms of dihydro-benzoxazole-6-yl-acetamide derivative and processes for their preparation
AU2010279963A1 (en)	2009-08-04	2012-02-23	Dainippon Sumitomo Pharma Co., Ltd.	Benzyl piperidine compound
SG10201507362TA (en)	2009-08-05	2015-10-29	Intra Cellular Therapies Inc	Novel Regulatory Proteins And Inhibitors
BR112012008346B1 (pt)	2009-09-11	2021-12-21	Vivoryon Therapeutics N.V.	Derivados heterocíclicos, seu processo de preparação, e composição farmacêutica
US8741343B2 (en)	2009-12-02	2014-06-03	Adamas Pharmaceuticals, Inc.	Method of administering amantadine prior to a sleep period
WO2011107530A2 (en)	2010-03-03	2011-09-09	Probiodrug Ag	Novel inhibitors
DK2545047T3 (da)	2010-03-10	2014-07-28	Probiodrug Ag	Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5)
EP2560953B1 (en)	2010-04-21	2016-01-06	Probiodrug AG	Inhibitors of glutaminyl cyclase
WO2012123563A1 (en)	2011-03-16	2012-09-20	Probiodrug Ag	Benz imidazole derivatives as inhibitors of glutaminyl cyclase
JP6411215B2 (ja)	2011-11-22	2018-10-24	ザリージェンツオブザユニバーシティオブカリフォルニア	虚血傷害を治療するためのシステアミンおよび／またはシスタミン
US9512096B2 (en)	2011-12-22	2016-12-06	Knopp Biosciences, LLP	Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9662313B2 (en)	2013-02-28	2017-05-30	Knopp Biosciences Llc	Compositions and methods for treating amyotrophic lateral sclerosis in responders
US10154971B2 (en)	2013-06-17	2018-12-18	Adamas Pharma, Llc	Methods of administering amantadine
US9468630B2 (en)	2013-07-12	2016-10-18	Knopp Biosciences Llc	Compositions and methods for treating conditions related to increased eosinophils
HRP20251187T1 (hr)	2013-07-12	2025-11-21	Areteia Therapeutics, Inc.	Liječenje povišenih razina eozinofila i/ili bazofila
US9642840B2 (en)	2013-08-13	2017-05-09	Knopp Biosciences, Llc	Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders
US9763918B2 (en)	2013-08-13	2017-09-19	Knopp Biosciences Llc	Compositions and methods for treating chronic urticaria
US10752588B2 (en)	2014-12-19	2020-08-25	The Broad Institute, Inc.	Dopamine D2 receptor ligands
US10633336B2 (en)	2014-12-19	2020-04-28	The Broad Institute, Inc.	Dopamine D2 receptor ligands
MX2020002078A (es)	2017-08-24	2020-09-21	Adamas Pharma Llc	Composiciones de amantadina, preparaciones de estas y métodos de uso.
PL3461819T3 (pl)	2017-09-29	2020-11-30	Probiodrug Ag	Inhibitory cyklazy glutaminylowej
US12521365B2 (en)	2019-04-26	2026-01-13	Cytosolve, Inc.	Compositions for improving brain health and memory

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE792187A (fr) *	1971-12-03	1973-03-30	Sumitomo Chemical Co	Nouveaux derives d'alkylamines
DE2845537A1 (de) *	1978-10-19	1980-04-30	Bayer Ag	Benzimidazolylcarbamidsaeureester, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
ZA848275B (en) *	1983-12-28	1985-08-28	Degussa	New piridine-2-ethers or pyridine-2-thioethers having a nitrogen-containing cycloaliphatic ring
EP0488959A3 (en)	1990-11-28	1992-08-05	Sandoz Ltd.	New uses of competitive nmda receptor antagonists
JPH05194505A (ja) *	1991-08-09	1993-08-03	Yoshitomi Pharmaceut Ind Ltd	チオフェン化合物
US5192751A (en)	1992-07-24	1993-03-09	Eli Lilly And Company	Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence
JP2959615B2 (ja) *	1993-06-24	1999-10-06	吉富製薬株式会社	縮合型チオフェン化合物およびその医薬用途
EP0709384B1 (de)	1994-10-31	1998-12-23	MERCK PATENT GmbH	Benzylpiperidinderivate mit hoher Affinität zu Bindungsstellen von Aminosäure-Rezeptoren
EP0825984A1 (en) *	1995-04-07	1998-03-04	Novo Nordisk A/S	Novel method
ZA9610741B (en) *	1995-12-22	1997-06-24	Warner Lambert Co	4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610745B (en) *	1995-12-22	1997-06-24	Warner Lambert Co	4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
JP2001501628A (ja) *	1996-10-04	2001-02-06	ノボノルディスクアクティーゼルスカブ	Ｎ―置換化アザ複素環式化合物
DE19643790A1 (de)	1996-10-30	1998-05-07	Merck Patent Gmbh	Benzoxazol-Derivat

1999
- 1999-06-24 PE PE1999000567A patent/PE20000728A1/es not_active Application Discontinuation
- 1999-06-25 US US09/674,298 patent/US6284774B1/en not_active Expired - Fee Related
- 1999-06-25 ES ES99931887T patent/ES2244201T3/es not_active Expired - Lifetime
- 1999-06-25 BR BR9911575-1A patent/BR9911575A/pt not_active Application Discontinuation
- 1999-06-25 AP APAP/P/2000/001949A patent/AP2000001949A0/en unknown
- 1999-06-25 JP JP2000556782A patent/JP2002519322A/ja active Pending
- 1999-06-25 SK SK1951-2000A patent/SK19512000A3/sk unknown
- 1999-06-25 TR TR2000/03888T patent/TR200003888T2/xx unknown
- 1999-06-25 ID IDW20002514A patent/ID28005A/id unknown
- 1999-06-25 PL PL99345024A patent/PL345024A1/xx unknown
- 1999-06-25 EA EA200100058A patent/EA200100058A1/ru unknown
- 1999-06-25 EE EEP200000778A patent/EE200000778A/xx unknown
- 1999-06-25 NZ NZ508808A patent/NZ508808A/xx unknown
- 1999-06-25 AT AT99931887T patent/ATE297207T1/de not_active IP Right Cessation
- 1999-06-25 OA OA1200000347A patent/OA11570A/en unknown
- 1999-06-25 CA CA002327888A patent/CA2327888A1/en not_active Abandoned
- 1999-06-25 IL IL13894999A patent/IL138949A0/xx unknown
- 1999-06-25 DE DE69925730T patent/DE69925730T2/de not_active Expired - Fee Related
- 1999-06-25 CN CN99807087A patent/CN1304307A/zh active Pending
- 1999-06-25 WO PCT/US1999/014291 patent/WO2000000197A1/en not_active Ceased
- 1999-06-25 AU AU48303/99A patent/AU769650B2/en not_active Ceased
- 1999-06-25 HU HU0102471A patent/HUP0102471A2/hu unknown
- 1999-06-25 KR KR1020007014745A patent/KR20010053170A/ko not_active Withdrawn
- 1999-06-25 EP EP99931887A patent/EP1089735B1/en not_active Expired - Lifetime
2000
- 2000-10-16 IS IS5667A patent/IS5667A/is unknown
- 2000-10-19 ZA ZA200005848A patent/ZA200005848B/en unknown
- 2000-12-19 NO NO20006482A patent/NO20006482L/no not_active Application Discontinuation
- 2000-12-21 BG BG105082A patent/BG105082A/xx unknown

Also Published As

Publication number	Publication date
IL138949A0 (en)	2001-11-25
EE200000778A (et)	2002-04-15
AU769650B2 (en)	2004-01-29
OA11570A (en)	2004-07-01
NO20006482D0 (no)	2000-12-19
BG105082A (en)	2001-09-28
ZA200005848B (en)	2001-12-18
BR9911575A (pt)	2001-03-20
HUP0102471A2 (hu)	2002-05-29
US6284774B1 (en)	2001-09-04
PL345024A1 (en)	2001-11-19
ES2244201T3 (es)	2005-12-01
AP2000001949A0 (en)	2000-12-31
EP1089735A4 (en)	2002-12-18
DE69925730D1 (de)	2005-07-14
EA200100058A1 (ru)	2001-08-27
PE20000728A1 (es)	2000-08-21
IS5667A (is)	2000-10-16
EP1089735A1 (en)	2001-04-11
DE69925730T2 (de)	2006-03-23
CN1304307A (zh)	2001-07-18
NZ508808A (en)	2002-12-20
JP2002519322A (ja)	2002-07-02
EP1089735B1 (en)	2005-06-08
ATE297207T1 (de)	2005-06-15
SK19512000A3 (sk)	2001-08-06
TR200003888T2 (tr)	2001-06-21
WO2000000197A1 (en)	2000-01-06
ID28005A (id)	2001-05-03
AU4830399A (en)	2000-01-17
KR20010053170A (ko)	2001-06-25
CA2327888A1 (en)	2000-01-06

Legal Events

Date	Code	Title	Description
2002-03-25	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20006482L (no)	2000-12-19	4-benzyl piperidinalkylsulfoksy-heterocykler og deres anvendelse som subtype-selektive NMDA reseptorantagonister
NO20013538L (no)	2001-09-17	Piperidin, tetrahydropyridin og piperazinderivater, deres fremstilling og anvendelse
NO960630L (no)	1996-02-16	Heterocykler anvendelige som neurokinin antagonister
NO20054082L (no)	2005-11-04	Pyrazol`1,5-A! 1,3,5! triazinderivater som kannabinoidreseptorligander
NO20055516L (no)	2005-11-22	Kannabinoidreceptorligander og anvendelser derav
PA8467101A1 (es)	2000-09-29	Compuestos 4-(2-ceto-1-benzilimidazolinil)piperidina como agonistas del receptor orli
TW200635897A (en)	2006-10-16	Piperidine derivatives and their use as anti-inflammatory agents
TR200100754T2 (tr)	2001-10-22	Glausomanın tedavi edilmesi için serotonerjik 5HT2.
ATE496893T1 (de)	2011-02-15	Isochinolinonderivate und deren verwendung als medikamente
TR200100137T2 (tr)	2001-05-21	Obesitenin ve başka bozuklukların tedavisinde yararlı nöropeptit Y Y5 reseptörü için ligandlar olarak N-ikameli aminotetralinler.
NO20015366L (no)	2002-01-03	Piperazinderivater som er anvendbare som CCR5-antagonister
SE9900100D0 (sv)	1999-01-15	New compounds
NO970831L (no)	1997-04-18	Nye substituerte piperidiner som er anvendbare for behandling av allergiske sykdommer
MX2010006230A (es)	2010-06-23	Derivados de arilamida substituidos con triazol y su uso como antagonistas de receptor purinergico p2x3 y/o p2x2/3.
CA2183954A1 (en)	1995-09-14	Treatment of Obsessive-Compulsive Disorders with 5-HT2 Antagonists
NO20075022L (no)	2007-10-04	(7-(2-(4-(3-trifluormetylfenyl)-1,2,3,6-tetrahydropyrid-1-yl)etyl) isokinolinbesylatsalt, fremstilling og terapeutiske anvendelser derav
NO20006460L (no)	2001-02-19	4, 5, 6 og 7-Indol og indolinderivater, deres fremstilling og anvendelse
NO20001934L (no)	2000-04-13	3-Substituerte tetrahydropyridopyrimidinon-derivater, deres fremstilling og anvendelse
NO20060702L (no)	2006-02-28	Aminokinolinderivater og deres anvendelse som adenosin A3 ligander
TR199700956T1 (xx)	1998-02-21	Indazolkarboksamidler.
NO20004144D0 (no)	2000-08-18	Heterocykliske forbindelser, deres fremstilling og anvendelse som takykinin reseptor antagonister
DK1390372T3 (da)	2008-09-15	1-oxa-3,9-diaza-spiro '5,5]undecan-2-on-derivater og anvendelse deraf som neurokininreceptorantagonist
AP2000002017A0 (en)	2000-12-31	Salts of paroxetine.
DK1185525T3 (da)	2007-06-04	4-heterocyclylsulfonamidyl-6-methoxy-5-(2-methoxy-phenoxy)-2-pyridyl-pyrimidinderivater, fremstilling deraf samt anvendelse deraf som endothelinreceptorantagonister
NO982863L (no)	1998-06-19	Nye forbindelser med analgetisk effekt